IMMUNEREGEN, NIAID TO COLLABORATE ON VIPROVEX

A A

ImmuneRegen BioSciences has announced an agreement with the National Institute of Allergy and Infectious Diseases (NIAID), a component of the NIH. The agreement states that the NIAID will fund and conduct a preclinical anti-microbial evaluation of ImmuneRegen's proprietary compound Viprovex for potential use as a possible treatment for certain infectious respiratory diseases including influenza, measles and SARS.

Viprovex is the trade name used in referring to formulations of Homspera for potential indications for treatment of maladies caused by exposure to various chemical and biological agents. All of the company's research and development efforts are early, pre-clinical stage and both Homspera and Viprovex have only undergone exploratory studies to evaluate their biological activity in small animals.